<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmitt,M.</style></author><author><style face="normal" font="default" size="100%">Depuydt,C.</style></author><author><style face="normal" font="default" size="100%">Benoy,I.</style></author><author><style face="normal" font="default" size="100%">Bogers,J.</style></author><author><style face="normal" font="default" size="100%">Jérôme Antoine</style></author><author><style face="normal" font="default" size="100%">M. Arbyn</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Epidemiol.Biomarkers Prev.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">accuracy</style></keyword><keyword><style  face="normal" font="default" size="100%">Antwerp</style></keyword><keyword><style  face="normal" font="default" size="100%">AS</style></keyword><keyword><style  face="normal" font="default" size="100%">at</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">Brussels</style></keyword><keyword><style  face="normal" font="default" size="100%">cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Case</style></keyword><keyword><style  face="normal" font="default" size="100%">cause</style></keyword><keyword><style  face="normal" font="default" size="100%">cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervical</style></keyword><keyword><style  face="normal" font="default" size="100%">cervical cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">CERVICAL-CANCER</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical</style></keyword><keyword><style  face="normal" font="default" size="100%">cytology</style></keyword><keyword><style  face="normal" font="default" size="100%">detection</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnostics</style></keyword><keyword><style  face="normal" font="default" size="100%">Dna</style></keyword><keyword><style  face="normal" font="default" size="100%">electronic</style></keyword><keyword><style  face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style  face="normal" font="default" size="100%">FOLLOW-UP</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">Germany</style></keyword><keyword><style  face="normal" font="default" size="100%">health</style></keyword><keyword><style  face="normal" font="default" size="100%">healthcare</style></keyword><keyword><style  face="normal" font="default" size="100%">HPV</style></keyword><keyword><style  face="normal" font="default" size="100%">Human</style></keyword><keyword><style  face="normal" font="default" size="100%">identify</style></keyword><keyword><style  face="normal" font="default" size="100%">INFECTION</style></keyword><keyword><style  face="normal" font="default" size="100%">infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Institute</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">LSIL</style></keyword><keyword><style  face="normal" font="default" size="100%">n</style></keyword><keyword><style  face="normal" font="default" size="100%">ON</style></keyword><keyword><style  face="normal" font="default" size="100%">Order</style></keyword><keyword><style  face="normal" font="default" size="100%">p</style></keyword><keyword><style  face="normal" font="default" size="100%">PCR</style></keyword><keyword><style  face="normal" font="default" size="100%">precursor</style></keyword><keyword><style  face="normal" font="default" size="100%">PROGRAM</style></keyword><keyword><style  face="normal" font="default" size="100%">public</style></keyword><keyword><style  face="normal" font="default" size="100%">public health</style></keyword><keyword><style  face="normal" font="default" size="100%">Public-health</style></keyword><keyword><style  face="normal" font="default" size="100%">qPCR</style></keyword><keyword><style  face="normal" font="default" size="100%">Quantitative real-time PCR</style></keyword><keyword><style  face="normal" font="default" size="100%">real time PCR</style></keyword><keyword><style  face="normal" font="default" size="100%">Real-time PCR</style></keyword><keyword><style  face="normal" font="default" size="100%">Research</style></keyword><keyword><style  face="normal" font="default" size="100%">result</style></keyword><keyword><style  face="normal" font="default" size="100%">results</style></keyword><keyword><style  face="normal" font="default" size="100%">Sample</style></keyword><keyword><style  face="normal" font="default" size="100%">Samples</style></keyword><keyword><style  face="normal" font="default" size="100%">scale</style></keyword><keyword><style  face="normal" font="default" size="100%">SCREENING</style></keyword><keyword><style  face="normal" font="default" size="100%">SENSITIVITY</style></keyword><keyword><style  face="normal" font="default" size="100%">specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Test</style></keyword><keyword><style  face="normal" font="default" size="100%">tests</style></keyword><keyword><style  face="normal" font="default" size="100%">threshold</style></keyword><keyword><style  face="normal" font="default" size="100%">thresholds</style></keyword><keyword><style  face="normal" font="default" size="100%">transformation</style></keyword><keyword><style  face="normal" font="default" size="100%">Type</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Load</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">12/2/2013</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">414</style></number><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">406 - 414</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Infections with high-risk human papillomaviruses (Hr-HPV) can cause malignant transformation of the human cervical epithelium. HPV DNA tests generally are very sensitive to detect cervical neoplastic lesions but also identify transient HPV infections. As a consequence, the specificity and positive predictive value are low.METHODS: We analyzed viral load of Hr- and possibly Hr-HPV types more than seven orders of magnitude (on a log10 scale) in 999 consecutive BD-SurePath liquid-based cervical cytology samples from routine cervical screening enriched with atypical squamous cells of undetermined significance (n = 100), low-grade squamous intraepithelial lesions (LSIL; n = 100), and high-grade squamous intraepithelial lesions (HSIL; n = 97) using type-specific multiplex quantitative real-time PCR and the BSGP5+/6+-PCR/MPG assay. In the 36-month follow-up, 79 histologically verified CIN2+ and 797 double-negative cytology cases were identified.RESULTS: Viral loads in LSIL and HSIL were significantly increased compared with no intraepithelial lesion or malignancy in both the quantitative PCR (qPCR) and BSGP5+/6+-PCR/MPG assay (P &lt; 0.0001). The mean viral loads in LSIL and HSIL were not significantly different. Using a newly determined high viral load cut off for 14 Hr-HPV types, the sensitivity for prevalent CIN3+ remained at 100% for both assays compared with the minimal detection threshold. The specificity (corresponding to double-negative cytology at subsequent screening episodes) increased substantially (qPCR, from 91.1% to 95.7%; BSGP5+/6+-PCR/MPG, from 79.8% to 96.2%).CONCLUSIONS: Compared with DNA positivity alone, high Hr-HPV viral loads could reduce the amount of false positive results detected by the BSGP5+/6+-PCR/MPG and qPCR by 81.4% and 52.1%, respectively.Impact: Quantitative type-specific HPV DNA assays show high flexibility in defining thresholds that allow optimizing clinical accuracy for cervical cancer precursors. Cancer Epidemiol Biomarkers Prev; 1-9. (c)2013 AACR</style></abstract><custom1><style face="normal" font="default" size="100%">35601</style></custom1><section><style face="normal" font="default" size="100%">406</style></section></record></records></xml>